EP2478906A1 — Latanoprost-containing aqueous eye drops and method for inhibiting adsorption of latanoprost to resin
Assigned to Senju Pharmaceutical Co Ltd · Expires 2012-07-25 · 14y expired
What this patent protects
The present invention provides an aqueous eye drop containing latanoprost, which is a preparation wherein decrease of an effective concentration of latanoprost due to adsorption to a resin is suppressed and the stability of latanoprost is improved. It is also an object of the pre…
USPTO Abstract
The present invention provides an aqueous eye drop containing latanoprost, which is a preparation wherein decrease of an effective concentration of latanoprost due to adsorption to a resin is suppressed and the stability of latanoprost is improved. It is also an object of the present invention to provide a method of suppressing adsorption of latanoprost to a resin. The present invention provides an aqueous eye drop containing latanoprost, a surfactant, and an aliphatic mono- or di-carboxylic acid having a carbon number of 3 - 10 or a salt thereof. In addition, the present invention provides a method of suppressing adsorption of latanoprost to a resin in an aqueous solution, including adding a surfactant, and an aliphatic mono- or di-carboxylic acid having a carbon number of 3 - 10 or a salt thereof.
Drugs covered by this patent
- Sandimmune (cyclosporine) · Novartis AG (originally Sandoz)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.